Antonio Di Stasi

机构：Università Cattolica del Sacro Cuore, University of Alabama at Birmingham Hospital, University of Alabama at Birmingham, Ospedale Sacro Cuore Don Calabria, O'Neal Comprehensive Cancer Center · ORCID：0000-0002-7886-3514

发表论文 106 篇 · 总被引 5695 次 · h-index 23

代表论文

• Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML (2019 · New England Journal of Medicine · 被引 1286)
• Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3 (2024 · Journal of Clinical Oncology · 被引 221)
• Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology (2020 · Journal of the National Comprehensive Cancer Network · 被引 122)
• Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study (2022 · Journal of Clinical Oncology · 被引 103)
• Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with FLT3 -mutated ( FLT3 mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial (2019 · Cancer Research · 被引 36)
• NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022 (2023 · Journal of the National Comprehensive Cancer Network · 被引 23)